Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer

Ching-Yu Wang(University of Florida), Xinyue Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mayur M. Amonkar(GlaxoSmithKline (United States)), Changxia Shao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward A. Bortnichak(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alicia C. McDonald(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Zhou(Broad Institute)
JCO Clinical Cancer Informatics
July 1, 2023
10.1200/cci.22.00184
Cited by 2

Related Papers

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
|The Lancet Oncology|2015|264
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156